• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by OS Therapies Incorporated

    7/16/25 5:04:45 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001795091
    OS THERAPIES Inc
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    OS Therapies Inc
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    OS Therapies Inc
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Grasonville MARYLAND 21638 410-297-7793

    3. Related Persons

    Last Name First Name Middle Name
    Romness Paul A.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chairman, President and Chief Executive Officer
    Last Name First Name Middle Name
    Petit Robert G.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Medical Officer and Chief Scientific Officer
    Last Name First Name Middle Name
    Acevedo Christopher P.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Ciccio John
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McKean Dieser Avril
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Galzahr Karim
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jarry Olivier
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Search Theodore F.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-06-23    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Ceros Financial Services, Inc. 37869
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    1445 Research Boulevard
    City State/Province/Country ZIP/Postal Code
    Rockville MARYLAND 20850
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $4,216,794 USD
    or    Indefinite
    Total Amount Sold $4,216,794 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    27

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $210,839 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    OS Therapies Inc /s/ Christopher P. Acevedo Christopher P. Acevedo Chief Financial Officer 2025-07-16

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $OSTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    SEC Filings

    See more
    • SEC Form D filed by OS Therapies Incorporated

      D - OS Therapies Inc (0001795091) (Filer)

      7/16/25 5:04:45 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - OS Therapies Inc (0001795091) (Filer)

      7/14/25 8:06:17 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - OS Therapies Inc (0001795091) (Filer)

      6/27/25 7:59:08 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

      Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

      10/28/24 4:44:00 PM ET
      $BMY
      $DRIO
      $NVS
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OS Therapies with a new price target

      Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

      4/2/25 8:01:55 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

      Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives for OS Animal Health, close out OST-504 (previously ADXS-504) prostate cancer study and initiate AI-driven next-gen tADC product candidate modelingNew York, New York--(Newsfile Corp. - July 14, 2025) - OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has closed its previously announced warrant exercise inducement and exchange offer. The Company raised a total of $4.2 milli

      7/14/25 7:40:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

      Current holders of five-year warrants with a current exercise price of $1.12 per share issued in connection with PIPE transaction initially closed on December 31, 2024 ("Old Warrants") offered opportunity to exercise Old Warrants now to receive new five-year warrants with an exercise price of $3.00 per share (the "New Warrants") Exercise of all Old Warrants would provide a maximum of ~$8 million in gross proceeds, $1.76 million of which has already been received by the Company, thereby extending cash runway into second half of 2026 OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical com

      6/23/25 8:29:00 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Former 10% Owner Auerbach Shalom

      4 - OS Therapies Inc (0001795091) (Issuer)

      5/9/25 9:45:04 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom sold $163,918 worth of shares (82,000 units at $2.00) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      5/9/25 9:30:13 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom sold $81,566 worth of shares (60,012 units at $1.36) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      4/11/25 9:45:07 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Financials

    Live finance-specific insights

    See more
    • OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

      Feedback from Type D FDA Meeting expected by mid-June 2025 to confirm statistical analysis methods to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation requests Completed Phase 2b trial data analysis using methods agreed to by FDA to be presented at MIB Factor on June 28, 2025 Company remains on track for Q3 2025 BLA filing for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial res

      5/16/25 6:00:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

      Company now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of

      4/9/25 7:40:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

      OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) & other tunable drug conjugates (tDC) platforms. The Company has initiated discussions with clinical-stage ADC therapeutics companies in the U.S., China and other jurisdictions to form joint ventures (JVs) pairing those companies' clinical-stage assets with certain assets f

      2/24/25 7:25:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by OS Therapies Incorporated

      SC 13G - OS Therapies Inc (0001795091) (Subject)

      8/28/24 4:30:09 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care